• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

由伏立康唑成功治疗的早期新生儿败血症罕见病例。

Rare case of early neonatal sepsis caused by successfully treated with voriconazole.

作者信息

Bhushan Shashi, Mahajan Supriya, Sen Aditya

机构信息

Department of Paediatrics, School of Medical Sciences and Research, Sharda University, Greater Noida, UP, India.

Department of Microbiology, School of Medical Sciences and Research, Sharda University, Greater Noida, UP, India.

出版信息

Med Mycol Case Rep. 2024 Jul 9;45:100659. doi: 10.1016/j.mmcr.2024.100659. eCollection 2024 Sep.

DOI:10.1016/j.mmcr.2024.100659
PMID:39108978
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC11301222/
Abstract

This study reports a case of multidrug resistant as the cause of early neonatal sepsis in a term small-for-gestational age neonate weighing 1680 g that successfully responded to voriconazole therapy. Both blood culture and urine culture of the neonate sent on day 4 and day 8 respectively showed Gram positive oval budding yeast cells on Gram staining which was confirmed as susceptible only to voriconazole by Vitek 2 Compact (Biomérieux, France) automated system. Voriconazole was given for fourteen days leading to good clinical response with microbiological clearance of fungus from blood and no side-effects.

摘要

本研究报告了一例孕周足月、出生体重1680g的小于胎龄新生儿，其早期新生儿败血症由多重耐药菌引起，对伏立康唑治疗反应良好。分别于第4天和第8天采集的新生儿血培养和尿培养，革兰氏染色均显示革兰氏阳性椭圆形芽生酵母细胞，经法国生物梅里埃公司的Vitek 2 Compact自动化系统确认，该菌仅对伏立康唑敏感。给予伏立康唑治疗14天，临床反应良好，血液中的真菌被清除，且无副作用。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f009/11301222/ec67a7165e5c/gr2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f009/11301222/6f8780e35659/gr1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f009/11301222/ec67a7165e5c/gr2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f009/11301222/6f8780e35659/gr1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f009/11301222/ec67a7165e5c/gr2.jpg

相似文献

1
Rare case of early neonatal sepsis caused by successfully treated with voriconazole.由伏立康唑成功治疗的早期新生儿败血症罕见病例。
Med Mycol Case Rep. 2024 Jul 9;45:100659. doi: 10.1016/j.mmcr.2024.100659. eCollection 2024 Sep.
2
Comparison of the Vitek 2 yeast susceptibility system with CLSI microdilution for antifungal susceptibility testing of fluconazole and voriconazole against Candida spp., using new clinical breakpoints and epidemiological cutoff values.比较 Vitek 2 酵母菌药敏系统与 CLSI 微量稀释法对氟康唑和伏立康唑抗念珠菌属的药敏试验，采用新的临床折点和流行病学切点值。
Diagn Microbiol Infect Dis. 2013 Sep;77(1):37-40. doi: 10.1016/j.diagmicrobio.2013.05.019. Epub 2013 Jul 16.
3
A new triazole, voriconazole (UK-109,496), blocks sterol biosynthesis in Candida albicans and Candida krusei.一种新型三唑类药物伏立康唑（UK-109,496）可阻断白色念珠菌和克鲁斯念珠菌中的甾醇生物合成。
Antimicrob Agents Chemother. 1997 Nov;41(11):2492-6. doi: 10.1128/AAC.41.11.2492.
4
Species Distribution and Antifungal Susceptibilities of Candida Species Isolated From Blood Culture.从血培养中分离出的念珠菌属的菌种分布及抗真菌药敏情况
Cureus. 2023 Apr 27;15(4):e38183. doi: 10.7759/cureus.38183. eCollection 2023 Apr.
5
Activity of voriconazole against Candida albicans and Candida krusei isolated since 1984.自1984年以来伏立康唑对白色念珠菌和克柔念珠菌的活性。
Int J Antimicrob Agents. 2000 Nov;16(3):205-9. doi: 10.1016/s0924-8579(00)00191-6.
6
Activities of fluconazole and voriconazole against bloodstream isolates of Candida glabrata and Candida krusei: a 14-year study in a Spanish tertiary medical centre.氟康唑和伏立康唑对光滑念珠菌和克柔念珠菌血流分离株的活性：西班牙一家三级医疗中心的14年研究。
Int J Antimicrob Agents. 2008 Mar;31(3):266-71. doi: 10.1016/j.ijantimicag.2007.09.010. Epub 2007 Dec 3.
7
Effects of voriconazole, granulocyte-macrophage colony-stimulating factor, and interferon gamma on intracellular fluconazole-resistant Candida glabrata and Candida krusei in human monocyte-derived macrophages.伏立康唑、粒细胞-巨噬细胞集落刺激因子和干扰素γ对人单核细胞衍生巨噬细胞内耐氟康唑光滑念珠菌和克柔念珠菌的影响。
Diagn Microbiol Infect Dis. 2005 Aug;52(4):299-304. doi: 10.1016/j.diagmicrobio.2005.02.017.
8
Genetic basis for differential activities of fluconazole and voriconazole against Candida krusei.氟康唑和伏立康唑对克柔念珠菌不同活性的遗传基础。
Antimicrob Agents Chemother. 2003 Apr;47(4):1213-9. doi: 10.1128/AAC.47.4.1213-1219.2003.
9
Comparison of Six Antifungal Susceptibilities of 11 Species Using the VITEK2 AST-YS08 Card and Broth Microdilution Method.采用 VITEK2 AST-YS08 卡和肉汤微量稀释法比较 11 种真菌的六种抗真菌药敏性。
Microbiol Spectr. 2022 Apr 27;10(2):e0125321. doi: 10.1128/spectrum.01253-21. Epub 2022 Apr 6.
10
Antifungal activity of voriconazole (UK-109,496), fluconazole and amphotericin B against hematogenous Candida krusei infection in neutropenic guinea pig model.伏立康唑（UK-109,496）、氟康唑和两性霉素B对中性粒细胞减少豚鼠模型血源性克柔念珠菌感染的抗真菌活性。
J Chemother. 1999 Feb;11(1):34-9. doi: 10.1179/joc.1999.11.1.34.

引用本文的文献

1
Congenital Sepsis in an Extremely Preterm Baby: Case Report and Literature Review.极早早产儿先天性败血症：病例报告与文献综述
Antibiotics (Basel). 2025 Jun 30;14(7):666. doi: 10.3390/antibiotics14070666.

本文引用的文献

1
Voriconazole plasma concentrations and dosing in paediatric patients below 24 months of age.24 个月以下儿科患者伏立康唑的血药浓度与剂量。
Mycoses. 2023 Nov;66(11):969-976. doi: 10.1111/myc.13643. Epub 2023 Aug 8.
2
Neonatal invasive candidiasis in low- and middle-income countries: Data from the NeoOBS study.中低收入国家新生儿侵袭性念珠菌病：NeoOBS 研究数据。
Med Mycol. 2023 Mar 2;61(3). doi: 10.1093/mmy/myad010.
3
Clinical Analysis of Intravenous and Oral Sequential Treatment With Voriconazole for Central Nervous System Infection in Six Premature Infants.
伏立康唑静脉与口服序贯治疗6例早产儿中枢神经系统感染的临床分析
Front Pharmacol. 2021 Jun 24;12:631293. doi: 10.3389/fphar.2021.631293. eCollection 2021.
4
Invasive Infections in Neonates after Major Surgery: Current Evidence and New Directions.新生儿大手术后的侵袭性感染：当前证据与新方向。
Pathogens. 2021 Mar 9;10(3):319. doi: 10.3390/pathogens10030319.
5
Initial use of voriconazole positively affects outcome of bloodstream infection: a retrospective analysis.伏立康唑的初始使用对血流感染的结局有积极影响：一项回顾性分析。
Transl Pediatr. 2020 Aug;9(4):480-486. doi: 10.21037/tp-20-37.
6
Prolonged Outbreak of Candida krusei Candidemia in Paediatric Ward of Tertiary Care Hospital.儿童病房中克柔念珠菌血症的长时间爆发。
Mycopathologia. 2020 Apr;185(2):257-268. doi: 10.1007/s11046-020-00427-y. Epub 2020 Jan 25.
7
Etiology and Outcome of Candidemia in Neonates and Children in Europe: An 11-year Multinational Retrospective Study.欧洲新生儿和儿童念珠菌血症的病因和结局：一项 11 年的跨国回顾性研究。
Pediatr Infect Dis J. 2020 Feb;39(2):114-120. doi: 10.1097/INF.0000000000002530.
8
Interaction of Candida Species with the Skin.念珠菌属与皮肤的相互作用。
Microorganisms. 2017 Jun 7;5(2):32. doi: 10.3390/microorganisms5020032.
9
Dose optimisation of voriconazole with therapeutic drug monitoring in children: a single-centre experience in China.中国单中心研究：治疗药物监测指导下伏立康唑的剂量优化。
Int J Antimicrob Agents. 2017 Apr;49(4):483-487. doi: 10.1016/j.ijantimicag.2016.11.028. Epub 2017 Jan 31.
10
Early-Onset Invasive Candidiasis in Extremely Low Birth Weight Infants: Perinatal Acquisition Predicts Poor Outcome.极低出生体重儿早发型侵袭性念珠菌病：围产期获得性感染预示不良结局。
Clin Infect Dis. 2017 Apr 1;64(7):921-927. doi: 10.1093/cid/cix001.